Richard Law Analyst Performance

Analyst at The Goldman Sachs Group

Richard Law is a stock analyst at The Goldman Sachs Group in the medical sector, covering 10 publicly traded companies. Over the past year, Richard Law has issued 16 stock ratings, including buy, hold, and sell recommendations. While full access to Richard Law's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Richard Law's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 16 Last 0 Years
Buy Recommendations: 43.75% 7 Buy Ratings
Companies Covered: 10 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	43.8%	7 ratings
Hold	50.0%	8 ratings
Sell	6.3%	1 ratings

Out of 16 total stock ratings issued by Richard Law at The Goldman Sachs Group, the majority (50.0%) have been Hold recommendations, followed by 43.8% Buy and 6.3% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	10 companies

Richard Law, an analyst at The Goldman Sachs Group, currently covers 10 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 10 companies	100.0%

Richard Law of The Goldman Sachs Group specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 8 companies	80.0%
MED - DRUGS 2 companies	20.0%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
MLTX MoonLake Immunotherapeutics	10/1/2025	Reiterated Rating	$6.98	$7.00	Neutral
MLTX MoonLake Immunotherapeutics	9/30/2025	Downgrade	$7.17	$7.00	Neutral
CRNX Crinetics Pharmaceuticals	9/26/2025	Boost Price Target	$45.58	$40.00	Neutral
MLYS Mineralys Therapeutics	9/9/2025	Boost Price Target	$37.15	$52.00	Buy
VRDN Viridian Therapeutics	8/7/2025	Boost Price Target	$16.57	$30.00	Buy
MLTX MoonLake Immunotherapeutics	8/6/2025	Boost Price Target	$52.25	$82.00	Buy
ARQT Arcutis Biotherapeutics	7/25/2025	Initiated Coverage	$15.02	$18.00	Neutral
OLMA Olema Pharmaceuticals	5/14/2025	Lower Price Target	$4.20	$18.00	Buy
RCKT Rocket Pharmaceuticals	5/9/2025	Lower Price Target	$7.00	$13.00	Neutral
CLDX Celldex Therapeutics	5/9/2025	Lower Price Target	$18.54	$31.00	Neutral
VRDN Viridian Therapeutics	5/7/2025	Lower Price Target	$12.30	$27.00	Buy
VKTX Viking Therapeutics	4/8/2025	Initiated Coverage	$21.52	$30.00	Neutral
RCKT Rocket Pharmaceuticals	3/3/2025	Lower Price Target	$9.15	$15.00	Neutral
MLYS Mineralys Therapeutics	2/13/2025	Lower Price Target	$10.36	$24.00	Buy
SLN Silence Therapeutics	2/11/2025	Initiated Coverage	$4.92	$6.00	Sell
MLTX MoonLake Immunotherapeutics	1/17/2025	Upgrade	$41.47	$82.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.